



## **H. Lundbeck A/S, a pharmaceutical company**

### **Currently Seeking Adult Patients Living with Episodic Cluster Headache for a Clinical Research Study**

H. Lundbeck A/S is currently running a study investigating the possible preventive treatment of episodic Cluster Headache. It targeted to patients between the ages of 18 and 75 which:

- Have a medical history of first symptoms of Cluster Headache at the age of 50 or prior
- Have a documented history of episodic Cluster Headache for at least 12 months
- Have a prior history of cluster period(s) lasting 6 weeks or longer, when untreated
- Can accurately distinguish between episodic Cluster Headache and other headaches

If you choose to participate, and the study is right for you, the study is between 25 and 77 weeks and will depend on when you enter a bout.

The study is divided into a screening period (between 1 and 52 weeks) and a treatment period. The treatment period starts with a placebo-controlled section where you will be randomised (shuffled) into an active or dummy treatment. After 4 weeks, you will switch to the other group. Neither you nor the study doctor nor the study staff will know which product you are receiving. This then is followed by a 20-week observational and follow up period.

You will also be asked to keep a headache diary from when you enter a bout until the end of the study.

#### **Find out more**

If you would like to learn more about the Alleviate Study or schedule a visit to determine if you may be eligible to participate, please reach out to the study sites for more information.

Prior to contacting a study site, we advise that you speak to your GP regarding the study

- King's College Hospital  
Primary Investigator: Peter Goadsby  
Contact: [headache-research@kcl.ac.uk](mailto:headache-research@kcl.ac.uk)
- Salford Royal NHS Foundation Trust  
Primary Investigator: Adam Zermansky  
Contact: [neuroresearch.nurse@nca.nhs.uk](mailto:neuroresearch.nurse@nca.nhs.uk) or 0161 206 5203
- Newcastle Upon Tyne Hospitals NHS Foundation Trust  
Primary Investigator: Paul Dorman  
Contact: [nuth.researchstudies@nhs.net](mailto:nuth.researchstudies@nhs.net) or 0191 2823172 (primary) or 0191 2823979